Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)
Phase of Trial: Phase IV
Latest Information Update: 20 May 2017
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms POWER
- Sponsors Novartis
- 17 May 2017 Status changed from recruiting to completed.
- 12 Apr 2015 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
- 12 Apr 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.